{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:46:20Z","timestamp":1792176380889,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To quantitatively assess the entrance angle variability and location of perforating scleral vessels (PSVs) in highly myopic eyes and to investigate its association with myopic choroidal neovascularisation (mCNV) versus lacquer cracks (LC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Entrance angles from the sclera to choroid were measured on each B-scan OCT using ImageJ and associated angle metrics were calculated per PSVs. Additional variables included subfoveal choroidal thickness (SFCT) and vessel-to-fovea distance (VFD). In mCNV eyes the total number of injections and treatment duration were also accounted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 42 eyes were included, 25 with mCNV and 17 with LC. Eyes with mCNV demonstrated significantly greater PSV angular variability including angular standard deviation, and their normalised metrics compared to LC eyes (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). VFD was shorter in the mCNV group (50.2\u2009\u00b1\u200952.6\u2009\u00b5m vs. 91.5\u2009\u00b1\u200939.6\u2009\u00b5m,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). Normalised angle metrics correlated positively with the total number of anti-VEGF injections (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009\u2248\u20090.37,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), whereas no association was observed with treatment duration. In multivariable regression, no predictors reached statistical significance although normalised angle range (NAR) showed a trend toward a negative association with VFD (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.060).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PSV angular variability was markedly greater in mCNV eyes and correlated with anti-VEGF injection burden reflecting higher treatment intensity but not longer disease duration. These findings suggest that PSV geometry influences LC and mCNV, may serve as an imaging biomarker of disease activity in mCNV. Shorter VFD and greater angular dispersion likely reflect structural and hemodynamic alterations predisposing to mCNV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04781-x","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T13:52:25Z","timestamp":1785592345000},"page":"2446-2453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perforating scleral vessel angular metrics as a structural biomarker of myopic choroidal neovascularisation"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0818-6124","authenticated-orcid":false,"given":"Alberto","family":"Quarta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2999-6782","authenticated-orcid":false,"given":"Alessandro","family":"Feo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Corradetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2661-5500","authenticated-orcid":false,"given":"Federico","family":"Corvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-1660","authenticated-orcid":false,"given":"Mai","family":"Alhelaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouzbeh","family":"Abbasgholizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Chujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-5968","authenticated-orcid":false,"given":"Marko","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceren","family":"Soylu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4745-8601","authenticated-orcid":false,"given":"Yu-Chien","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Duck","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneeswar G.","family":"Nittala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Staurenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-3306","authenticated-orcid":false,"given":"Srinivas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"4781_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/iovs.62.5.5","volume":"62","author":"K Ohno-Matsui","year":"2021","unstructured":"Ohno-Matsui K, Wu PC, Yamashiro K, et al. IMI pathologic myopia. Investig Opthalmol Vis Sci. 2021;62:5 https:\/\/doi.org\/10.1167\/iovs.62.5.5.","journal-title":"Investig Opthalmol Vis Sci"},{"key":"4781_CR2","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","volume":"124","author":"CMG Cheung","year":"2017","unstructured":"Cheung CMG, Arnold JJ, Holz FG, et al. Myopic choroidal neovascularization. Ophthalmology. 2017;124:1690\u2013711. https:\/\/doi.org\/10.1016\/j.ophtha.2017.04.028.","journal-title":"Ophthalmology"},{"key":"4781_CR3","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s00417-023-06320-w","volume":"262","author":"A Feo","year":"2024","unstructured":"Feo A, De Simone L, Cimino L, Angi M, Romano MR. Differential diagnosis of myopic choroidal neovascularization (mCNV): insights from multimodal imaging and treatment implications. Graefes Arch Clin Exp Ophthalmol. 2024;262:2005\u201326. https:\/\/doi.org\/10.1007\/s00417-023-06320-w.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4781_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/IAE.0000000000003290","volume":"42","author":"J Ruiz-Medrano","year":"2022","unstructured":"Ruiz-Medrano J, Almazan-Alonso E, Flores-Moreno I, Puertas M, Garc\u00eda-Zamora M, Ruiz-Moreno JM. Relationship between myopic choroidal neovascularization activity and perforating scleral vessels in high myopia. Retina. 2022;42:204\u20139. https:\/\/doi.org\/10.1097\/IAE.0000000000003290.","journal-title":"Retina"},{"key":"4781_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1065397","volume":"9","author":"W Yao","year":"2022","unstructured":"Yao W, Xu J, She X, et al. Perforating scleral vessels adjacent to myopic choroidal neovascularization achieved a poor outcome after intravitreal anti-VEGF therapy. Front Med. 2022;9:1065397. https:\/\/doi.org\/10.3389\/fmed.2022.1065397.","journal-title":"Front Med"},{"key":"4781_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000544750","volume":"248","author":"J Ruiz-Medrano","year":"2025","unstructured":"Ruiz-Medrano J, Almaz\u00e1n-Alonso E, Puertas M, et al. Optical coherence tomography imaging of perforating scleral vessels and dilated choroidal veins as potential image markers in myopic choroidal neovascularization using optical coherence tomography angiography. Ophthalmologica. 2025;248:160\u20137. https:\/\/doi.org\/10.1159\/000544750.","journal-title":"Ophthalmologica"},{"key":"4781_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-024-00374-5","volume":"11","author":"X She","year":"2024","unstructured":"She X, Yao W, Huang G, et al. Myopic choroidal neovascularization with neovascular signal around perforating scleral vessel prone to recur after anti-VEGF therapy. Eye Vis. 2024;11:6. https:\/\/doi.org\/10.1186\/s40662-024-00374-5.","journal-title":"Eye Vis"},{"key":"4781_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ajo.2015.07.017","volume":"160","author":"G Querques","year":"2015","unstructured":"Querques G, Corvi F, Balaratnasingam C, et al. Lacquer cracks and perforating scleral vessels in pathologic myopia: a possible causal relationship. Am J Ophthalmol. 2015;160:759\u2013.e2. https:\/\/doi.org\/10.1016\/j.ajo.2015.07.017.","journal-title":"Am J Ophthalmol"},{"key":"4781_CR9","doi-asserted-by":"publisher","first-page":"7637","DOI":"10.1167\/iovs.13-12981","volume":"54","author":"A Pedinielli","year":"2013","unstructured":"Pedinielli A, Souied EH, Perrenoud F, Leveziel N, Caillaux V, Querques G. In vivo visualization of perforating vessels and focal scleral ectasia in pathological myopia. Investig Opthalmol Vis Sci. 2013;54:7637. https:\/\/doi.org\/10.1167\/iovs.13-12981.","journal-title":"Investig Opthalmol Vis Sci"},{"key":"4781_CR10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1097\/IAE.0000000000001686","volume":"38","author":"SP Rothenbuehler","year":"2018","unstructured":"Rothenbuehler SP, Maloca P, Scholl HPN, et al. Three-dimensional analysis of submacular perforating scleral vessels by enhanced depth imaging optical coherence tomography. Retina. 2018;38:1231\u20137. https:\/\/doi.org\/10.1097\/IAE.0000000000001686.","journal-title":"Retina"},{"key":"4781_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s44172-024-00280-7","volume":"3","author":"K Ito","year":"2024","unstructured":"Ito K, Hoerig C, Dan YS, McFadden SA, Mamou J, Hoang QV. Biomechanical changes occur in myopic choroidal stroma and mirror those in the adjacent sclera. Commun Eng. 2024;3:139. https:\/\/doi.org\/10.1038\/s44172-024-00280-7.","journal-title":"Commun Eng"},{"key":"4781_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/IAE.0b013e3182a6b494","volume":"34","author":"K Shinohara","year":"2014","unstructured":"Shinohara K, Moriyama M, Shimada N, Tanaka Y, Ohno-Matsui K. Myopic stretch lines: linear lesions in fundus of eyes with pathologic myopia that differ from lacquer cracks. Retina. 2014;34:461\u20139. https:\/\/doi.org\/10.1097\/IAE.0b013e3182a6b494.","journal-title":"Retina"},{"key":"4781_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.preteyeres.2018.10.005","volume":"69","author":"J Ruiz-Medrano","year":"2019","unstructured":"Ruiz-Medrano J, Montero JA, Flores-Moreno I, Arias L, Garc\u00eda-Layana A, Ruiz-Moreno JM. Myopic maculopathy: current status and proposal for a new classification and grading system (ATN). Prog Retin Eye Res. 2019;69:80\u2013115. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.10.005.","journal-title":"Prog Retin Eye Res"},{"key":"4781_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004605","author":"N Castellino","year":"2025","unstructured":"Castellino N, Rubegni G, Brinkmann M, et al. Factors influencing the number of anti-VEGF injections in myopic choroidal neovascularization: a multicenter study. Retina. 2025. https:\/\/doi.org\/10.1097\/IAE.0000000000004605.","journal-title":"Retina"},{"key":"4781_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OPTH.S269162","volume":"ume 15","author":"MR Cheema","year":"2021","unstructured":"Cheema MR, DaCosta J, Talks J. Ten-year real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration. Clin Ophthalmol. 2021;ume 15:279\u201387. https:\/\/doi.org\/10.2147\/OPTH.S269162.","journal-title":"Clin Ophthalmol"},{"key":"4781_CR16","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41433-024-02998-2","volume":"38","author":"CJ Payne","year":"2024","unstructured":"Payne CJ, Gupta U, Maatouk CM, et al. Real-world effects of anti-vascular endothelial growth factor injection frequency on visual outcomes in patients with diabetic macular oedema. Eye Lond Engl. 2024;38:1687\u201393. https:\/\/doi.org\/10.1038\/s41433-024-02998-2.","journal-title":"Eye Lond Engl"},{"key":"4781_CR17","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s00417-021-05505-5","volume":"260","author":"J Hanhart","year":"2022","unstructured":"Hanhart J, Wiener R, Totah H, et al. Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2022;260:1907\u201314. https:\/\/doi.org\/10.1007\/s00417-021-05505-5.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4781_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40123-025-01098-y","volume":"14","author":"P Wojciechowski","year":"2025","unstructured":"Wojciechowski P, Wdowiak M, Panek M, et al. Efficacy, safety, and injection frequency with novel aflibercept 8 mg in neovascular age-related macular degeneration: a comparison with existing anti-VEGF regimens using a Bayesian network meta-analysis. Ophthalmol Ther. 2025;14:733\u201353. https:\/\/doi.org\/10.1007\/s40123-025-01098-y.","journal-title":"Ophthalmol Ther"},{"key":"4781_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.survophthal.2023.10.013","volume":"69","author":"A Feo","year":"2024","unstructured":"Feo A, Stradiotto E, Sacconi R, Menean M, Querques G, Romano MR. Subretinal hyperreflective material in retinal and chorioretinal disorders: a comprehensive review. Surv Ophthalmol. 2024;69:362\u201377. https:\/\/doi.org\/10.1016\/j.survophthal.2023.10.013.","journal-title":"Surv Ophthalmol"},{"key":"4781_CR20","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","volume":"120","author":"A Tufail","year":"2013","unstructured":"Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013;120:1944\u2013.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2013.06.010.","journal-title":"Ophthalmology"},{"key":"4781_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000001797","author":"A Quarta","year":"2025","unstructured":"Quarta A, He Y, Corradetti G, et al. Intraretinal sclero-choroidal vessels in eyes with severe chorioretinal thinning: hypothesis on Bruch\u2019s membrane failure. Retin Cases Brief Rep. 2025. https:\/\/doi.org\/10.1097\/ICB.0000000000001797.","journal-title":"Retin Cases Brief Rep"},{"key":"4781_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ajo.2016.03.019","volume":"166","author":"K Ohno-Matsui","year":"2016","unstructured":"Ohno-Matsui K, Jonas JB, Spaide RF. Macular bruch membrane holes in highly myopic patchy chorioretinal atrophy. Am J Ophthalmol. 2016;166:22\u201328. https:\/\/doi.org\/10.1016\/j.ajo.2016.03.019.","journal-title":"Am J Ophthalmol"},{"key":"4781_CR23","doi-asserted-by":"publisher","unstructured":"Quarta A, Feo A, Corradetti G, Popovic MM, Sadda SR. Double layer sign in chorioretinal diseases: Clinical significance and implications from multimodal imaging. Surv Ophthalmol. 2025. https:\/\/doi.org\/10.1016\/j.survophthal.2025.09.017","DOI":"10.1016\/j.survophthal.2025.09.017"},{"key":"4781_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004793","author":"A Quarta","year":"2026","unstructured":"Quarta A, Abbasgholizadeh R, Soylu C, Sadda SR. Evolution of intraretinal sclerochoroidal vessels over two years follow-up. Retina. 2026. https:\/\/doi.org\/10.1097\/IAE.0000000000004793.","journal-title":"Retina"},{"key":"4781_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1167\/iovs.67.1.43","volume":"67","author":"A Quarta","year":"2026","unstructured":"Quarta A, Feo A, Romano F, et al. Localized choriocapillaris flow deficits at perforating vessel sites in myopic eyes. Invest Ophthalmol Vis Sci. 2026;67:43. https:\/\/doi.org\/10.1167\/iovs.67.1.43.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4781_CR26","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1097\/IAE.0000000000003852","volume":"43","author":"J Ruiz-Medrano","year":"2023","unstructured":"Ruiz-Medrano J, Almaz\u00e1n-Alonso E, Puertas M, et al. Assessment and role of artery\u2013vein complex in myopic choroidal neovascularization using optical coherence tomography angiography. Retina. 2023;43:1544\u20139. https:\/\/doi.org\/10.1097\/IAE.0000000000003852.","journal-title":"Retina"},{"key":"4781_CR27","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.5301\/ejo.5000875","volume":"27","author":"C Giuffr\u00e8","year":"2017","unstructured":"Giuffr\u00e8 C, Querques L, Carnevali A, De Vitis LA, Bandello F, Querques G. Choroidal neovascularization and coincident perforating scleral vessels in pathologic myopia. Eur J Ophthalmol. 2017;27:e39\u2013e45. https:\/\/doi.org\/10.5301\/ejo.5000875.","journal-title":"Eur J Ophthalmol"},{"key":"4781_CR28","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"S Wolf","year":"2014","unstructured":"Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121:682\u2013.e2. https:\/\/doi.org\/10.1016\/j.ophtha.2013.10.023.","journal-title":"Ophthalmology"},{"key":"4781_CR29","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Y Ikuno","year":"2015","unstructured":"Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization. Ophthalmology. 2015;122:1220\u20137. https:\/\/doi.org\/10.1016\/j.ophtha.2015.01.025.","journal-title":"Ophthalmology"},{"key":"4781_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/bjophthalmol-2014-305131","volume":"99","author":"TY Wong","year":"2015","unstructured":"Wong TY, Ohno-Matsui K, Leveziel N, et al. Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol. 2015;99:289\u201396. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305131.","journal-title":"Br J Ophthalmol"},{"key":"4781_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ajo.2022.08.005","volume":"244","author":"W Cheng","year":"2022","unstructured":"Cheng W, Song Y, Gao X, et al. Axial length and choriocapillaris flow deficits in non-pathological high myopia. Am J Ophthalmol. 2022;244:68\u201378. https:\/\/doi.org\/10.1016\/j.ajo.2022.08.005.","journal-title":"Am J Ophthalmol"},{"key":"4781_CR32","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1136\/bjo-2022-323020","volume":"108","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Bo W, Yang Z, Luo X, Ni Y, Zeng J. Choriocapillaris flow features in children with myopic anisometropia. Br J Ophthalmol. 2024;108:1578\u201382. https:\/\/doi.org\/10.1136\/bjo-2022-323020.","journal-title":"Br J Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04781-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04781-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04781-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:55:40Z","timestamp":1792173340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04781-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":32,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4781"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04781-x","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the other authors has any competing interests or financial disclosures. SS has the following disclosures: Consultant (C): 4DMT, Abbvie, Alexion, Allergan Inc., Alnylam Pharmaceuticals, Amgen Inc., Apellis Pharmaceuticals, Inc., Astellas, Bayer Healthcare Pharmaceuticals, Biogen MA Inc., Boehringer Ingelheim, Carl Zeiss Meditec, Catalyst Pharmaceuticals Inc., Centervue Inc., GENENTECH, Gyroscope Therapeutics, Heidelberg Engineering, Hoffman La Roche, Ltd., Iveric Bio, Janssen Pharmaceuticals Inc., Nanoscope, Notal Vision Inc., Novartis Pharma AG, Optos Inc., Oxurion\/Thrombogenics, Oyster Point Pharma, Regeneron Pharmaceuticals Inc., Samsung Bioepis, Topcon Medical Systems Inc. Recipient (R): Carl Zeiss Meditec, Heidelberg 35 Engineering, Nidek Incorporated, Novartis Pharma AG, Topcon Medical Systems Inc. Financial Support 36 (F): Carl Zeiss Meditec, Heidelberg Engineering, Optos Inc., Nidek, Topcon, Centervue. GS disclosures: Carl Zeiss Meditec, Centervue, Inc., Heidelberg Engineering, Hoffman La Roche, Ltd., Nidek, Inc., Novartis Pharmaceuticals, Optos, Inc., RetinAI; Royalties e Ocular Instruments Inc; Consultant e AbbVie, Apellis Pharmaceuticals, Inc., Annexon Bioscience, Bayer Healthcare Pharmaceuticals, Boehringer, Centervue, Inc., Genentech, Heidelberg Engineering, Hoffman La Roche, Ltd., Iveric Bio, Medscape, Novartis Pharmaceuticals, Optos, Inc., RetinAI; Honoraria e Carl Zeiss, Heidelberg Engineering, Hoffman La Roche, Ltd., Meditec, Nidek, Inc., Novartis Pharmaceuticals. FR disclosures: Roche (R), patent through Massachusetts Eye and Ear (U.S. 63\/381,925). MP disclosures: Financial support (to institution): Bayer, Fighting Blindness Canada, PSI Foundation, Honoriarium: Astellas, Bayer, Roche.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}